ProKidney Corp. (PROK)
1.83
-0.02
(-1.08%)
USD |
NASDAQ |
Sep 10, 16:00
1.83
0.00 (0.00%)
After-Hours: 20:00
ProKidney Enterprise Value : 1.309B for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | 1.309B |
| September 08, 2026 | 1.338B |
| September 04, 2026 | 1.342B |
| September 03, 2026 | 1.323B |
| September 02, 2026 | 1.321B |
| September 01, 2026 | 1.309B |
| August 31, 2026 | 1.317B |
| August 28, 2026 | 1.305B |
| August 27, 2026 | 1.303B |
| August 26, 2026 | 1.286B |
| August 25, 2026 | 1.284B |
| August 24, 2026 | 1.260B |
| August 21, 2026 | 1.260B |
| August 20, 2026 | 1.220B |
| August 19, 2026 | 1.233B |
| August 18, 2026 | 1.212B |
| August 17, 2026 | 1.216B |
| August 14, 2026 | 1.202B |
| August 13, 2026 | 1.217B |
| August 12, 2026 | 1.233B |
| August 11, 2026 | 1.260B |
| August 10, 2026 | 1.276B |
| August 07, 2026 | 1.266B |
| August 06, 2026 | 1.266B |
| August 05, 2026 | 1.272B |
| Date | Value |
|---|---|
| August 04, 2026 | 1.264B |
| August 03, 2026 | 1.249B |
| July 31, 2026 | 1.245B |
| July 30, 2026 | 1.253B |
| July 29, 2026 | 1.245B |
| July 28, 2026 | 1.245B |
| July 27, 2026 | 1.245B |
| July 24, 2026 | 1.237B |
| July 23, 2026 | 1.241B |
| July 22, 2026 | 1.243B |
| July 21, 2026 | 1.256B |
| July 20, 2026 | 1.249B |
| July 17, 2026 | 1.262B |
| July 16, 2026 | 1.260B |
| July 15, 2026 | 1.257B |
| July 14, 2026 | 1.247B |
| July 13, 2026 | 1.260B |
| July 10, 2026 | 1.290B |
| July 09, 2026 | 1.299B |
| July 08, 2026 | 1.307B |
| July 07, 2026 | 1.329B |
| July 06, 2026 | 1.338B |
| July 02, 2026 | 1.346B |
| July 01, 2026 | 1.317B |
| June 30, 2026 | 1.348B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.44B |
| Oncolytics Biotech, Inc. | 95.42M |
| Sangamo Therapeutics, Inc. | 55.96M |
| Sarepta Therapeutics, Inc. | 2.583B |
| Anixa Biosciences, Inc. | 82.91M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -46.44M |
| Revenue (Quarterly) | 0.15M |
| Total Expenses (Quarterly) | 28.57M |
| EPS Diluted (Quarterly) | -0.1524 |
| Gross Profit Margin (Quarterly) | -866.0% |
| Profit Margin (Quarterly) | -30.96K% |
| Earnings Yield | -30.19% |
| Normalized Earnings Yield | -30.19 |